Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes

Blood

Volumn 90, Issue 10, 1997, Pages 3819-3843

  Colman, Robert W ^b   Schmaier, Alvin H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

KININOGEN; PREKALLIKREIN;

AMINO ACID SEQUENCE; ANTICOAGULATION; CELL ACTIVITY; CELL ADHESION; CELL MEMBRANE; ENDOTHELIUM CELL; FIBRINOLYSIS; GENE EXPRESSION; PRIORITY JOURNAL; REVIEW; RNA PROCESSING; STRUCTURE ACTIVITY RELATION;

EID: 0030830360     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.10.3819     Document Type: Review

References (296)

1. Roche e Silva M, Beraldo WT, Rosenfeld G: Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Physiol 150:261, 1949
2. Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaraes JA, Pierce JV, Kaplan AP: Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 56:1650, 1975
3. Wuepper KD, Miller DR, Lacombe MJ: Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest 56:1663, 1975
4. Saito H, Ratnoff OD, Waldmann R, Abraham JP: Fitzgerald trait: Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular permeability (PF/DIL). J Clin Invest 55:1082, 1975
5. Takagaki Y, Kitamura N, Nakanishi S: Cloning and sequence analysis of cDNAs for human high molecular weight and low molecular weight prekininogens. Primary structures of two human prekininogens. J Biol Chem 260:8601, 1985
6. Kitamura N, Kitagawa H, Fukushima D, Takagaki Y, Miyata T, Nakanishi S: Structural organization of the human kininogen gene and a model for its evolution. J Biol Chem 260:8610, 1985
7. Fong D, Smith DI, Hsieh WT: The human kininogen gene (KNG) mapped to chromosome 3q26-qter by analysis of somatic cell hybrids using the polymerase chain reaction. Hum Genet 87:189, 1991
8. Cheung PP, Cannizzaro LA, Colman RW: Chromosomal mapping of human kininogen gene (KNG) to 3q26→qter. Cytogenet Cell Genet 59:24, 1992
9. Rizzu P, Baldini A: Three members of the human cystatin gene superfamily, AHSG, HRG, and KNG, map within one megabase of genomic DNA at 3q27. Cytogenet Cell Genet 70:26, 1995
10. Kakizuka A, Ingi T, Murai T, Nakanishi S: A set of U1 snRNA-complementary sequences involved in governing alternative RNA splicing of the kininogen genes. J Biol Chem 265:10102, 1990
11. Cheung PP, Kunapuli SP, Scott CF, Wachtfogel YT, Colman RW: Genetic basis of total kininogen deficiency in Williams' trait. J Biol Chem 268:23361, 1993
12. Hayashi I, Hoshiko S, Makabe O, Oh-ishi S: A point mutation of alanine 163 to threonine is responsible for the defective secretion of high molecular weight kininogen by the liver of brown Norway Katholiek rats. J Biol Chem 268:17219, 1993
13. Chen LM, Chung P, Chao S, Chao L, Chao J: Differential regulation of kininogen gene expression by estrogen and progesterone in vivo. Biochim Biophys Acta 1131:145, 1992
14. Chhibber G, Cohen A, Lane S, Farber A, Meloni FJ, Schmaier AH: Immunoblotting of plasma in a pregnant patient with hereditary angioedema. J Lab Clin Med 115:112, 1990
15. Takano M, Yokoyama K, Yayama K, Okamoto H: Murine fibroblasts synthesize and secrete kininogen in response to eyclic-AMP, prostaglandin E2 and tumor necrosis factor. Biochim Biophys Acta 1265:189, 1995
16. Scott CF, Colman RW: Sensitive antigenic determinations of high molecular weight kininogen performed by covalent coupling of capture antibody. J Lab Clin Med 119:77, 1992
17. Jacobsen S, Kriz M: Some data on two purified kininogens from human plasma. Br J Pharmacol 29:25, 1967
18. Schmaier AH, Bradford H, Silver LD, Farber A, Scott CF, Schutsky D, Colman RW: High molecular weight kininogen is an inhibitor of platelet calpain. J Clin Invest 77:1565, 1986
19. Schmaier AH, Zuckerberg A, Silverman C, Kuchibhotla J, Tuszynski GP, Colman RW: High-molecular weight kininogen. A secreted platelet protein. J Clin Invest 71:1477, 1983
20. Schmaier AH, Kuo A, Lundberg D, Murray S, Cines DB: The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 263:16327, 1988
21. Gustafson EJ, Schmaier AH, Wachtfogel YT, Kaufman N, Kucich U, Colman RW: Human neutrophils contain and bind high molecular weight kininogen. J Clin Invest 84:28, 1989
22. Proud D, Perkins M, Pierce JV, Yates KN, Highet PF, Herring PL, Mangkornkanok/Mark M, Bahu R, Carone F, Pisano JJ: Characterization and localization of human renal kininogen. J Biol Chem 256:10634, 1981
23. Hallbach J, Adams G, Wirthensohn G, Guder WG: Quantification of kininogen in human renal medulla. Biol Chem Hoppe Seyler 368:1151, 1987
24. Yamamoto T, Tsuruta J, Kambara T: Interstitial-tissue localization of high-molecular-weight kininogen in guinea-pig skin. Biochim Biophys Acta 916:332, 1987
25. Ohkubo I, Kurachi K, Takasawa T, Shiokawa H, Sasaki M: Isolation of a human cDNA for alpha 2-thiol proteinase inhibitor and its identity with low molecular weight kininogen. Biochemistry 23:5691, 1984
26. Weisel JW, Nagaswami C, Woodhead JL, DeLa Cadena RA, Page JD, Colman RW: The shape of high molecular weight kininogen: Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J Biol Chem 269:10100, 1994
27. Salvesen G, Parkes C, Abrahamson M, Grubb A, Barrett AJ: Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem J 234:429, 1986
28. Schmaier AH, Schutsky D, Farber A, Silver LD, Bradford HN, Colman RW: Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. J Biol Chem 262:1405, 1987
29. Vogel R, Assfalg-Machleidt I, Esterl A, Machleidt W, Muller-Esterl W: Proteinase-sensitive regions in the heavy chain of low molecular weight kininogen map to the inter-domain junctions. J Biol Chem 263:12661, 1988
30. Bradford HN, Jameson BA, Adam AA, Wassell RP, Colman RW: Contiguous binding and inhibitory sites on kininogens required for the inhibition of platelet calpain. J Biol Chem 268:26546, 1993
31. Hasan AA, Cines DB, Ngaiza JR, Jaffe EA, Schmaier AH: High-molecular-weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelium. Blood 85:3134, 1995
32. Hasan AA, Zhang J, Samuel M, Schmaier AH: Conformational changes in low molecular weight kininogen alters its ability to bind to endothelial cells. Thromb Haemost 74:1088, 1995
33. Asakura S, Hurley RW, Skorstengaard K, Ohkubo I, Mosher DF: Inhibition of cell adhesion by high molecular weight kininogen. J Cell Biol 116:465, 1992
34. Ishiguro H, Higashiyama S, Ohkubo I, Sasaki M: Heavy chain of human high molecular weight and low molecular weight kininogen binds calcium ion. Biochemistry 26:7021, 1987
35. Zini JM, Schmaier AH, Cines DB: Bradykinin regulates the expression of kininogen binding sites on endothelial cells. Blood 81:2936, 1993
36. Gustafson EJ, Schutsky D, Knight L, Schmaier AH: High molecular weight kininogen binds to unstimulated platelets. J Clin Invest 78:310, 1986
37. Greengard JS, Heeb MJ, Ersdal E, Walsh PN, Griffin JH: Binding of coagulation factor XI to washed human platelets. Biochemistry 25:3884, 1986
38. van Iwaarden F, deGroot PG, Bouma BN: The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem 263:4698, 1988
39. Croxatto HR, Boric MP, Roblero J, Albertini R, Silva R: Digestive process and regulation of renal excretory function. Pepsanurin and prokinins inhibitors of diuresis mediated by atrial natriuretic peptide. Rev Med Chile 122:1162, 1995
40. Bradford HN, Schmaier AH, Colman RW: Kinetics of inhibition of platelet calpain II by human kininogens. Biochem J 270:83, 1990
41. Auerswald EA, Rossler D, Mentele R, Assfalg-Machleidt I: Cloning, expression and characterization of human kininogen domain 3. FEBS Lett 321:93, 1993
42. Ylinenjarvi K, Prasthofer TW, Martin NC, Bjork I: Interaction of cysteine proteinases with recombinant kininogen domain 2, expressed in Escherichia coli. FEBS Lett 357:309, 1995
43. Bano B, Kunapuli SP, Bradford HN, Colman RW: Structural requirements for cathepsin B and cathepsin H inhibition by kininogens. J Protein Chem 15:519, 1996
44. Scott CF, Whitaker EJ, Hammond BF, Colman RW: Purification and characterization of a potent 70-kDa thiol lysyl-proteinase (Lys-gingivain) from Porphyromonas gingivalis that cleaves kininogens and fibrinogen. J Biol Chem 268:7935, 1993
45. Schmaier AH, Smith PM, Purdon AD, White JG, Colman RW: High molecular weight kininogen: Localization in the unstimulated and activated platelet and activation by a platelet calpain(s). Blood 67:119, 1986
46. Schmaier AH, Bradford HN, Lundberg D, Farber A, Colman RW: Membrane expression of platelet calpain. Blood 75:1273, 1990
47. Saido T, Suzuki H, Yamazaki H, Tanoue K, Suzuki K: In situ capture of m-calpain activation of platelets. J Biol Chem 268:7422, 1993
48. Meloni FJ, Schmaier AH: Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. J Biol Chem 266:6786, 1991
49. Reddigari SR, Kuna P, Miragliotta G, Shibayama Y, Nishikawa K, Kaplan AP: Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains. Blood 81:1306, 1993
50. Jiang YP, Muller Esterl W, Schmaier AH: Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. J Biol Chem 267:3712, 1992
51. Wachtfogel YT, DeLa Cadena RA, Kunapuli SP, Rick L, Miller M, Schultze RL, Altieri DC, Edgington TS, Colman RW: High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J Biol Chem 269:19307, 1994
52. Bode W, Engh R, Musil D, Thiele U, Huber R, Karshikov A, Brzin J, Kos J, Turk V: The 2.0 A X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. EMBO J 7:2593, 1988
53. Herwald H, Hasan AAK, Godovac-Zimmermann J, Schmaier AH, Muller-Esterl W: Identification of an endothelial cell binding site on kininogen domain D3. J Biol Chem 270:14634, 1995
54. DeLa Cadena RA, Wyshock EG, Kunapuli SP, Schultze RL, Miller M, Walz DA, Colman RW: Platelet thrombospondin interactions with human high and low molecular weight kininogens. Thromb Haemost 72:125, 1994
55. Puri RN, Zhou F, Hu CJ, Colman RF, Colman RW: High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets. Blood 77:500, 1991
56. Hasan AAK, Amenta S, Schmaier AH: Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of α-thrombin-induced platelet activation. Circulation 94:517, 1996
57. Kunapuli SP, Bradford HN, Jameson BA, DeLa Cadena RA, Rick L, Wassell RP, Colman RW: Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 domain 3 in the heavy chain of high molecular weight kininogen. J Biol Chem 271:11228, 1996
58. Mori K, Nagasawa S: Studies on human high molecular weight (HMW) kininogen. II. Structural change of HMW kininogen by the action of human plasma kallikrein. J Biochem 89:1465, 1981
59. Schmaier AH, Farber A, Schein R, Sprung C: Structural changes of plasma high molecular weight kininogen after in vitro activation and in sepsis. J Lab Clin Med 112:182, 1988
60. Tayeh MA, Olson ST, Shore JD: Surface-induced alterations in the kinetic pathway for cleavage of human high molecular weight kininogen by plasma kallikrein. J Biol Chem 269:16318, 1994
61. Wiggins RC: Kinin release from high molecular weight kininogen by the action of Hageman factor in the absence of kallikrein. J Biol Chem 258:8963, 1983
62. Scott CF, Silver LD, Purdon AD, Colman RW: Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. J Biol Chem 260:10856, 1985
63. Sato F, Nagasawa S: Mechanism of kinin release from human low-molecular-mass-kininogen by the synergistic action of human plasma kallikrein and leukocyte elastase. Biol Chem Hoppe Seyler 369:1009, 1988
64. Kleniewski J, Donaldson VH: Granulocyte elastase cleaves human high molecular weight kininogen and destroys its clot-promoting activity. J Exp Med 167:1895, 1988
65. Hasan AAK, Cines DB, Zhang J, Schmaier AH: The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain. J Biol Chem 269:31822, 1994
66. Meloni FJ, Gustafson EJ, Schmaier AH: High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage. Blood 79:1233, 1992
67. Hasan AAK, Cines DB, Herwald H, Schmaier AH, Muller-Esterl W: Mapping the cell binding site on high molecular weight kininogen domain 5. J Biol Chem 270:19256, 1995
68. Khan M, Punia N, Majluf-Cruz A, Kunapuli SP, Cooper SL, DeLa Cadena RA, Colman RW: The binding sites on high molecular weight kininogen (HK) to activated human neutrophils are localized to K263-Q292, Q329-M357, and H493-K520. Blood 86:33a, 1995 (abstr, suppl 1)
69. Retzios AD, Rosenfeld R, Schiffman S: Effects of chemical modifications on the surface-and protein-binding properties of the light chain of human high molecular weight kininogen. J Biol Chem 262:3074, 1987
70. Kunapuli SP, DeLa Cadena RA, Colman RW: Deletion mutagenesis of high molecular weight kininogen light chain: Identification of two anionic surface binding subdomains. J Biol Chem 268:2486, 1993
71. Bjork I, Olson ST, Sheffer RG, Shore JD: Binding of heparin to human high molecular weight kininogen. Biochemistry 28:1213, 1989
72. DeLa Cadena RA, Colman RW: The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependet binding to an anionic surface. Protein Sci 1:151, 1992
73. Ben Nasr AB, Herwald H, Muller-Esterl W, Bjorck L: Human kininogens interact with M protein, a bacterial surface protein and virulence determinant. Biochem J 305:173, 1995
74. Scott CF, Silver LD, Schapira M, Colman RW: Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. J Clin Invest 73:954, 1984
75. Tait JF, Fujikawa K: Identification of the binding site for plasma prekallikrein in human high molecular weight kininogen. A region from residues 185 to 224 of the kininogen light chain retains full binding activity. J Biol Chem 261:15396, 1986
76. Tait JF, Fujikawa K: Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J Biol Chem 262:11651, 1987
77. Vogel R, Kaufmann J, Chung DW, Kellermann J, Muller-Esterl W: Mapping of the prekallikrein binding site of human H-kininogen by ligand screening of lambda gt11 expression libraries: Mimicking of the predicted binding site by anti-idiotypic antibodies. J Biol Chem 265:12494, 1990
78. Bock PE, Shore JD: Protein-protein interactions in contact activation of blood coagulation. Characterization of fluorescein-labeled human high molecular weight kininogen-light chain as a probe. J Biol Chem 258:15079, 1983
79. Bock PE, Shore JD, Tans G, Griffin JH: Protein-protein interactions in contact activation of blood coagulation. Binding of high molecular weight kininogen and the 5-(iodoacetamido) fluorescein-labeled kininogen light chain to prekallikrein, kallikrein, and the separated kallikrein heavy and light chains. J Biol Chem 260:12434, 1985
80. Scarsdale JN, Harris RB: Solution phase conformation studies of the prekallikrein binding domain of high molecular weight kininogen. J Protein Chem 9:647, 1990
81. You JL, Scarsdale JN, Harris RB: Calorimetric and spectroscopic examination of the solution phase structures of prekallikrein binding domain peptides of high molecular weight kininogen. J Protein Chem 10:301, 1991
82. You JL, Page JD, Scarsdale JN, Colman RW, Harris RB: Conformational analysis of synthetic peptides encompassing the factor XI and prekallikrein overlapping binding domains of high molecular weight kininogen. Peptides 14:867, 1993
83. Reddigari S, Kaplan AP: Monoclonal antibody to human high molecular weight kininogen recognizes its prekallikrein binding site and inhibits coagulant activity. Blood 74:695, 1989
84. Kaufmann J, Haasemann M, Modrow S, Muller-Esterl W: Structural dissection of the multidomain kininogens. Fine mapping of the target epitopes of antibodies interfering with their functional properties. J Biol Chem 268:9079, 1993
85. Lenich C, Pannell R, Gurewich V: Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture. Thromb Haemost 74:698, 1995
86. Motta G, Rojkjaer R, Hasan AAK, Cines DB, Schmaier AH: High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: A novel mechanism for contact activation. Blood (in press)
87. Beaubien G, Rosinski-Chupin I, Mattei MG, Mbikay M, Chretien M, Seidah NG: Gene structure and chromosomal localization of plasma kallikrein. Biochemistry 30:1628, 1991
88. Asakai R, Davie EW, Chung DW: Organization of the gene for human factor XI. Biochemistry 26:7221, 1987
89. Chung DW, Fujikawa K, McMullen BA, DAvie EW: Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 25:2410, 1986
90. McMullen BA, Fujikawa K, Davie EW: Location of the disulfide bonds in human plasma prekallikrein: The presence of four novel apple domains in the amino-terminal portion of the molecule. Biochemistry 30:2050, 1991
91. McMullen BA, Fugikawa K, Davie EW: Location of the disulfide bonds in human coagulation factor XI: The presence of a Tandem apple domain. Biochemistry 30:2056, 1991
92. Mandle RJ Jr, Kaplan AP: Hageman factor substrates. Human plasma prekallikrein: Mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J Biol Chem 252:6097, 1977
93. Scott CF, Liu CY, Colman RW: Human plasma prekallikrein: A rapid high yield method for purification. Eur J Biochem 100:77, 1979
94. Fisher CA, Schmaier AH, Addonizio VP, Colman RW: Assay of prekallikrein in human plasma: Comparison of amidolytic, esterolytic, coagulation, and immunochemical assays. Blood 59:963, 1982
95. McConnell DJ, Mason B: The isolation of human plasma prekallikrein. Br J Pharmacol 38:490, 1970
96. Wuepper KD, Cochrane CG: Plasma prekallikrein: Isolation, characterization, and mechanism of action. J Exp Med 135:1, 1972
97. Burger D, Schleuning W-D, Schapira M: Human plasma prekallikrein: Immunoaffinity purification and activation to α-and β-kallikrein. J Biol Chem 261:324, 1986
98. Colman RW, Wachtfogel YT, Kucich U, Weinbaum G, Hahn S, Pixley RA, Scott CF, de Agostini A, Burger D, Schapira M: Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties. Blood 65:311, 1985
99. Mandle R Jr, Colman RW, Kaplan AP: Identification of prekallikrein and high molecular weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 73:4179, 1976
100. Page JD, Colman RW: Localization of distinct functional domains on prekallikrein for interaction with both high molecular weight kininogen and activated factor XII in a 28-kDa fragment (amino acids 141-371). J Biol Chem 266:8143, 1991
101. Page JD, You JL, Harris RB, Colman RW: Localization of the binding site on plasma kallikrein for high molecular weight kininogen to both apple 1 and apple 4 domains of the heavy chain. Arch Biochem Biophys 314:159, 1994
102. Hock J, Vogel R, Linke RP, Muller-Esterl W: High molecular weight kininogen-binding site of prekallikrein probed by monoclonal antibodies. J Biol Chem. 265:12005, 1990
103. Lin Y, Shenoy S, Harris RB, Colman RW: Direct evidence for multi-facial contacts between high molecular weight kininogen and plasma prekallikrein. Biochemistry 35:12945, 1996
104. Herwald H, Renne T, Meijers JCM, Chung D, Page JD, Colman RW, Muller-Esterl W: Mapping of the discontinuous kininogen binding site of prekallikrein. J Biol Chem 271:13061, 1996
105. Gigli I, Mason JW, Colman RW, Austen KF: Interaction of plasma kallikrein with the C1 inhibitor. J Immunol 104:574, 1970
106. Van der Graff F, Koedam JA, Bouma BA: Inactivation of Kallikrein in plasma. J Clin Invest 71:149, 1983
107. Schapira M, Scott CF, Colman RW: Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 69:462, 1982
108. Van der Graff F, Koedam JA, Griffin JH, Bouma BN: Interaction of human plasma, kallikrein and its light chain with C1 inhibitor. Biochemistry 22:4860, 1983
109. Schapira M, Scott CF, James A, Silver LD, Kueppers F, James HL, Colman RW: High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. Biochemistry 21:567, 1982
110. Schapira M, Scott CF, Colman RW: Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry 20:2738, 1981
111. Schmaier AH, Gustafson EG, Idell S, Colman RW: Plasma prekallikrein assay: Reversible inhibition of C1 inhibitor by chloroform and its use in measuring prekallikrein in different mammalian species. J Lab Clin Med 104:882, 1984
112. Lahiri B, Bagdasarian A, Mitchell B, Rosenberg RD, Colnian RW: Antithrombin-heparin cofactor: An inhibitor of plasma Kallikrein. Arch Biochem Biophys 175:737, 1976
113. Meijers JCM, Kanters DHAJ, Vlooswijk RAA, Erp HEV, Hessing M, Bouma BN: Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry 27:4231, 1988
114. Espana F, Estelles A, Griffin JH, Aznar J: Interaction of plasma kallikrein with protein C inhibitor in purified mixtures and in plasma. Thromb Haemost 65:46, 1991
115. Hauert J, Nicoloso G, Schleuning WD, Bachmann F, Schapira M: Plasminogen activators in dextran sulfate-activated euglobulin functions: A molecular analysis of factor XII and prekallikrein-dependent fibrinolysis. Blood 73:994, 1989
116. Ichinose A, Fujikawa K, Suyama T: The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 261:3486, 1986
117. Citarella F, Tripodi M, Fantoni A, Bernardi F, Romeo G, Rocchi M: Assignment of human coagulation factor XII (fXII) to chromosome 5 by cDNA hybridization to DNA from somatic cell hybrids. Hum Genet 80:397, 1988
118. Rolye NJ, Nigli M, Cool D, MacGilivray RTA, Hamerton JL: Structural gene encosing human factor XII is located at 5q33-qter. Somat Cell Mol Genet 14:217, 1988
119. Cool DE, MacGillivray RTA: Characterization of the human blood coagulation factor XII gene. J Biol Chem 262:13662, 1987
120. Cool DE, Edgell C-JS, Louie GV, Zoller MJ, Brayer GD, MacGillivray RTA: Characterization of human blood coagulation factor XII cDNA. J Biol Chem 260:13666, 1985
121. Que BG, Davie EW: Characterization of a cDNA coding for human factor XII (Hageman factor). Biochemistry 25:1525, 1986
122. Griffin JH, Cochrane CG: Human factor XII (Hageman factor). Methods Enzymol 45:56, 1976
123. Revak SD, Cochrane CC, Johnston A, Hugli T: Structural changes accompanying enzymatic activation of Hageman factor. J Clin Invest 54:619, 1974
124. Saito H, Ratnoff OD, Pensky J: Radioimmunoassay of human Hageman factor (factor XII). J Lab Clin Med 88:506, 1976
125. Gordon EM, Gallagher CA, Johnson TR, Blossey BK, Ilan J: Hepatocytes express blood coagulation factor XII (Hageman factor). J Lab Clin Med 115:463, 1990
126. Gordon EM, Williams SR, Frenchek B, Mazur CA, Speroff L: Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XII. J Lab Clin Med 111:52, 1988
127. Mitropoulos KA, Martin JC, Burgess Al, Esnouf MP, Stirling Y, Howorth DJ, Reeves BE: The increased rate of activation of factor XII in late pregnancy can contribute to the increased reactivity of factor VII. Thromb Haemost 63:349, 1990
128. Gordon EM, Johnson TR, Ramos LP, Schmeidler-Sapiro KT: Enhanced expression of factor XII (Hageman factor) in isolated livers of estrogen-and prolactin-treated rats. J Lab Clin Med 117:353, 1991
129. Farsetti A, Misiti S, Citarella F, Felici A, Andreoli M, Fantoni A, Sacchi A, Pontecorvi A: Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 136:5076, 1995
130. Schmeidler-Sapiro KT, Ratnoff OD, Gordon EM: Mitogenic effects of coagulation factor XII and factor XIIa on HepG2 cells. Proc Natl Acad Sci USA 88:4382, 1991
131. Gordon EM, Venkatesan N, Salazar R, Tang H, Schmeidler K, Buckley S, Warburton D, Hall FL: Factor XII-induced mitogenesis is mediated via a distinct signal transduction pathway that activates a mitogen-activated protein kinase. Proc Natl Acad Sci USA 93:2174, 1996
132. Pixley RA, Stumpo LG, Birkmeyer K, Silver L, Colman RW: A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation. J Biol Chem 262:10140, 1987
133. Clarke BJ, Cote HCF, Cool DE, Clark-Lewis I, Saito H, Pixley RA, Colman RW, MacGillivary RTA: Mapping of a putative surface-binding site of human coagulation factor XII. J Biol Chem 264:11497, 1989
134. Citrella F, Ravon DM, Pascucci B, Felici A, Fantoni A, Hack CE: Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces, Eur J Biochem 238:240, 1996
135. Cochrane CG, Revak SD, Wuepper KD: Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J Exp Med 138:1564, 1973
136. Samuel M, Pixley RA, Villanueva MA, Colman RW, Villanueva GB: Human factor XII (Hageman factor) autoactivation by dextran sulfate: Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J Biol Chem 267:19691, 1992
137. Pixley RA, Schapira M, Colman RW: Effect of heparin on the inactivation rate of human activated factor XII by antithrombin III. Blood 66:198, 1985
138. 571 to Ser substitution. Proc Natl Acad Sci USA 86:8319, 1989
139. Wuillemin WA, Huber I, Furlan M, Lammle B: Functional characterization of an abnormal factor XII molecule (F XII Bern). Blood 78:997, 1991
140. Cochrane CG, Revak SD, Wuepper KD: Activation of Hageman factor in solid and fluid phases: A critical role of kallikrein. J Exp Med 138:1564, 1973
141. Revak SD, Cochrane CG, Griffin JH: The binding and cleavage characteristics of huma Hageman factor during contact activation: a comparison of normal plasma with plasma deficient in factor XI, prekallikrein or high molecular weight kininogen. J Clin Invest 59:1167, 1977
142. Griffin JH: The role of surface in the surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci USA 75:1998, 1978
143. Kirby E, McDevitt PJ: The binding of bovine factor XII to kaolin. Blood 61:652, 1983
144. Wiggins RC, Cochrane CG: The autoactivation of rabbit Hageman factor. J Exp Med 150:1122, 1979
145. Miller G, Silverberg M, Kaplan AP: Autoactivability of human Hageman factor. Biochem Biophys Res Commun 92:803, 1980
146. Silverberg M, Dunn JT, Garen L, Kaplan AP: Autoactivation of human Hageman factor: Demonstration utilizing a synthetic substrate. J Biol Chem 255:7281, 1980
147. Dunn JT, Silverberg M, Kaplan AP: The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem 257:1779, 1982
148. Espana F, Ratnoff OD: Activation of Hageman factor (factor XII) by sulfatides and other agents in the absence of plasma proteases. J Lab Clin Med 102:31, 1983
149. Tankersley DL, Finlayson JS: Kinetics of activation and autoactivation of human factor XII. Biochemistry 23:273, 1984
150. Schousboe I: Contact activation in human plasma is triggered by zinc ion modulation of factor XII (Hageman factor). Blood Coagul Fibrinolysis 4:671, 1993
151. Bernardo MM, Day DE, Olson ST, Shore JD: Surface-independent acceleration of factor XII activation by zinc ions. I. Kinetic characterization of the metal ion rate enhancement. J Biol Chem 268:12468, 1993
152. Bernardo MM, Day DE, Halvorson HR, Olson ST, Shore JD: Surface-independent acceleration of factor XII activation by zinc ions. II. Direct binding and fluorescence studies. J Biol Chem 268:12477, 1993
153. 2+ binding sites in factor XII and its activation derivatives. Eur J Biochem 247:491, 1997
154. Wiggins RC, Loskutoff DJ, Cochrane CG, Griffin JH: Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. J Clin Invest 65:197, 1980
155. Bagdasarian A, Talamo RC, Colman RW: Isolation of the high molecular weight activators of prekallikrein. J Biol Chem 248:7742, 1973
156. Kaplan AP, Austen FK: A prealbumin activator of prekallikrein. J Immunol 105:802, 1970
157. Wuepper KD, Tucker ES III, Cochrane CG: Plasma Kinin system: Proenzyme components. J Immunol 105:1307, 1970
158. Cochrane CG, Griffin JH: Molecular assembly in the contact phase of the Hageman factor system. Am J Med 67:657, 1979
159. Kaplan AP, Austen FK: A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 133:696, 1971
160. Revak SD, Cochrane CG, Bouma BN, Griffin JH: Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med 147:719, 1978
161. Revak SD, Cochrane CG: The relationship of structure and function in human Hageman factor. The association of enzymatic binding activities with separate regions of the molecule. J Clin Invest 57:852, 1976
162. Forbes CO, Pensky J, Ratnoff OD: Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified C1-inactivator. J Lab Clin Med 76:809, 1970
163. Schreiber AD, Kaplan AD, Austen FK: Inhibition by C1-INH of Hageman factor fragment activation of coagulation, fibrinolysis and kinin-generation. J Clin Invest 52:1402, 1973
164. de Agostini A, Lijnen HR, Pixley RA, Colman RW, Schapira M: Inactivation of factor XII active fragment in normal plasma: Predominant role of C1-inhibitor. J Clin Invest 73:1542, 1984
165. Pixley RA, Schapira M, Colman RW: The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem 260:1723, 1985
166. Pixley RA, Schmaier AH, Colman RW: Effect of negatively charged activating compounds on inactivation of factor XIIa by C1 inhibitor. Arch Biochem Biophys 256:490, 1987
167. Stead NW, Kaplan AP, Rosenberg RD: The inhibition of human activated Hageman factor (HF) by human antithrombin-heparin cofactor (AT). J Biol Chem 251:6481, 1976
168. Pixley RA, Colman RW: Effect of heparin on the inactivation rate of human activated factor XII by antithrombin III. Blood 66:198, 1985
169. Berrettini M, Schleef RR, Espana F, Loskutoff DJ, Griffin JH: Interaction of type 1 plasminogen activator inhibitor with the enzymes of the contact activation system. J Biol Chem 264:11738, 1989
170. Kleniewski J, Donaldson VH: Endothelial cells produce a substance that inhibits contact activation of coagulation by blocking the activation of Hageman factor. Proc Natl Acad Sci USA 90:198, 1993
171. Greengard JS, Griffin JH: Receptors for high molecular weight kininogen on stimulated washed human platelets. Biochemistry 23:6863, 1984
172. van Iwaarden F, de Groot PG, Sixma JJ, Berrettini M, Bouma BN: High-molecular weight kininogen is present in cultured human endothelial cells: Localization, isolation, and characterization. Blood 71:1268, 1988
173. Kerbiriou-Nabias DM, Garcia FO, Larrieu MJ: Radioimmunoassays of human high and low molecular weight kininogens in plasmas and platelets. Br J Haematol 56:273, 1984
174. Figueroa CD, Henderson LM, Kaufmann J, DeLa Cadena RA, Colman RW, Muller-Esterl W, Bhoola KD: Immunovisualization of high (HK) and low (LK) molecular weight kininogens on isolated human neutrophils. Blood 79:759, 1992
175. Gustafson EJ, Lukasiewicz H, Wachtfogel YT, Norton KJ, Schmaier AH, Niewiarowski S, Colman RW: High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils and platelets. J Cell Biol 109:377, 1989
176. Berrettini M, Schleef RR, Heeb MJ, Hopmeier P, Griffin JH: Assembly and expression of an intrinsic factor IX activator complex on the surface of cultured human endothelial cells. J Biol Chem 267:19833, 1992
177. Jencks WP: On the attribution and additivity of binding energies. Proc Natl Acad Sci USA 78:4046, 1981
178. Villanueva GB, Leung L, Bradford H, Colman RW: Conformation of high molecular weight kininogen: Effects of kallikrein and factor XIa cleavage. Biochem Biophys Res Commun 158:72, 1989
179. Edgell CJS, McDonald CC, Graham JB: Permanent cell lines expressing human factor VHI-related antigen established by hybridization. Proc Natl Acad Sci USA 80:3734, 1983
180. Herwald H, Dedio J, Kellner R, Loos M, Mueller-Esterl W: Isolation and characterization of the kininogen-binding protein p33 from endothelial cells: Identity with the gC1q receptor. J Biol Chem 271:13040, 1996
181. Ghebrehiwet B, Lim BL, Peerschke EI, Willis AC, Reid KB: Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q. J Exp Med 179:1809, 1994
182. Joseph K, Ghebrehiwet B, Peerschke EIB, Reid KBM, Kaplan AP: Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: Identity with the receptor that binds to the globular "heads" of C1q (gC1qR). Proc Natl Acad Sci USA 93:8552, 1996
183. Dedio J, Mueller-Esterl W. Kininogen binding protein p33/ gC1qR is localized in the vesicular fraction of endothelial cells. FEBS Lett 399:255, 1996
184. Reddigari SR, Shibayama Y, Brunnee T, Kaplan AP: Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 268:11982, 1993
185. Colman RW, Pixley RA, Najamunnisa S, Yan W-Y, Wang J, Mazar A, McCrae KR: High molecular weight kininogen binds to the vitronectin binding domain(s) on the endothelial cell receptor. Circulation 94:I-42, 1996 (abstr)
186. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA: Regulation of integrin function by the urokinase receptor. Science 273:1551, 1996
187. 186a. Sheng N, Fairbanks M, Henrikson R, Canziani G, Chaiken I, Moser D, Colman RW: The integrin, CD11b/CD18 (Mac-1) is a major cell receptor for high molecular weight kininogen (HK). FASEB J 11:19920, 1997 (abstr)
188. Hasan AAK, Zisman T, Schmaier AH: Cytokeratin 1 is the major cell receptor for kininogens. Thromb Haemost 77:141, 1997 (abstr, suppl 1)
189. Hembrough TA, Vasudevan J, Allietta MM, Glass WF II, Gonias SL: A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surface of hepatocytes, HepG2 cells, and breast carcinoma cell line. J Cell Sci 108:1071, 1995
190. Hembrough TA, Li L, Gonias SL: Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem 271:25684, 1996
191. Nishikawa K, Shibayama Y, Kuna P, Calcaterra E, Kaplan AP, Reddigari SR: Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein. Blood 80:1980, 1992
192. Sinha D, Seaman FS, Koshy A, Knight LC, Walsh PN: Blood coagulation factor XIa binds specifically to a site on activated human platelets distinct from that for factor XI. J Clin Invest 73:1550, 1984
193. Walsh PN, Sinha D, Koshy A, Seaman FS, Bradford H: Functional characterization of platelet-bound factor XIa: Retention of factor XIa activity on the platelet surface. Blood 68:225, 1986
194. Loza JP, Gurewich V, Johnstone M, Pannell R: Plateletbound prekallikrein promotes pro-urokinase-induced clot lysis: A mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost 71:347, 1994
195. Kaplan AP, Kay AR, Austen KF: A prealbumin activator of prekallikrein II. Appearance of chemotactic activity for human neutrophils by the conversion of prekallikrein to kallikrein. J Exp Med 135:81, 1972
196. Schapira M, Despland E, Scott CF, Boxer LA, Colman RW: Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 69:1199, 1982
197. Wachtfogel YT, Kucich U, James HL, Scott CF, Schapira M, Zimmerman M, Cohen AB, Colman RW: Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 72:1672, 1983
198. Zimmerli W, Huber I, Bouma BN, Lammle B: Purified human plasma kallikrein does not stimulate but primes neutrophils for Superoxide production. Thromb Haemost 62:1121, 1989
199. Plow EF: Leukocyte elastase release during blood coagulation: A potential mechanism for activation of the alternative fibrinolytic pathway. J Clin Invest 69:564, 1982
200. Rebuck JW: The skin window as a monitor of leukocytic functions in contact activation factor deficiencies in man. Am J Clin Pathol 79:405, 1983
201. Colman RW, Wachtfogel YT, Kucich U, Weinbaum G, Hahn S, Pixley RA, Scott CF, DeAgostini A, Burger D, Schapira M: Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties. Blood 65:311, 1985
202. Wachtfogel YT, Pixley RA, Kucich U, Abrams W, Weinbaum G, Schapira M, Colman RW: Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 67:1731, 1986
203. Chien P, Pixley RA, Stumpo LG, Colman RW, Schreiber AD: Modulation of the human monocyte binding site for monomeric immunoglobulin G by activated Hageman factor. J Clin Invest 82:1554, 1988
204. Chien P, Pixley RA, Ruiz P, Colman RW, Schreiber AD: Modulation of the human monocyte FcgR1 by activated Hageman factor: Mapping the functional XIIa site. Blood 76:178a, 1990(abstr, suppl 1)
205. Toossi Z, Sedor JR, Mettler MA, Everson B, Young T, Ratnoff OD: Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). Proc Natl Acad Sci USA 89:11969, 1992
206. Crutchley DJ, Ryan JW, Ryan US, Fisher GH: Bradykinin-induced release of prostacyclin and thromboxanes from bovine pulmonary artery endothelial cells. Studies with lower homologs and calcium antagonists. Biochim Biophys Acta 751:99, 1983
207. Hong SL: Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. Thromb Res 18:787, 1980
208. Holland JA, Pritchard KA, Pappolla MA, Wolin MS, Rogers NJ, Stemerman MB: Bradykinin induces Superoxide anion release from human endothelial cells. J Cell Physiol 143:21, 1990
209. Smith D, Gilbert M, Owen WG: Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 66:835, 1983
210. Brown NJ, Nadeau JH, Vaughan DE: Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 77:522, 1997
211. Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor. Nature 327:524, 1987
212. Nakashima M, Mombouli JV, Taylor AA, Vanhoutte PM: Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest 92:2867, 1993
213. Boulanger C, Schini VB, Moncada S, Vanhoutte PM: Stimulation of cyclic GMP production in cultured endothelial cells of the pig by bradykinin, adenosine diphosphate, calcium ionophore A23187 and nitric oxide. Br J Pharmacol 101:152, 1990
214. Schini VB, Boulanger C, Regoli D, Vanhoutte PM: Bradykinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells. J Pharmacol Exp Ther 252:581, 1990
215. Busse R, Mulsch A: Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 275:87, 1990
216. Imai T, Hirata Y, Kanno K, Marumo F: Induction of nitric oxide synthase by cyclic AMP in rat vascular smooth muscle cells. J Clin Invest 93:543, 1994
217. Dixon BS, Breckon R, Fortune J, Vavrek RJ, Stewart JM, Marzec-Calvert R, Linas SL: Effects of kinins on cultured arterial smooth muscle. Am J Physiol 258:C299, 1990
218. Dixon BS, Sharma RV, Dickerson T, Fortune J: Bradykinin and angiotensin II: Activation of protein kinase C in arterial smooth muscle. Am J Physiol 266:C1406, 1994
219. McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P, Fujisaki J, Aldrich RW, Jarnagin K: Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci USA 88:7724, 1991
220. Menke JG, Borkowski JA, Bierilo K, MacNeil T, Derrick A, Schneck KA, Ransom RW, Strader CD, Linemayer DL, Hess JF: Expression cloning of a human B1 bradykinin receptor. J Biol Chem 269:21583, 1994
221. Madeddu P, Parpaglia PP, Demontis MP, Varoni MV, Fattaccio MC, Anania V, Glorioso N: Early blockade of bradykinin B2-receptors alters the adult cardiovascular phenotype in rats. Hypertension 25:453, 1995
222. Wiemer G, Scholkens BA, Linz W: Endothelial protection by converting enzyme inhibitors. Cardiovasc Res 28:166, 1994
223. Parratt JR: Cardioprotection by angiotensin converting enzyme inhibitors-the experimental evidence. Circ Res 28:183, 1994
224. Linz W, Wiemer G, Scholkens BA: ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. Mol Cell Cardiol 24:909, 1992
225. Linz W, Scholkens BA: Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharm 20:S83, 1992 (suppl 9)
226. Gohlke P, Linz W, Scholkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T: Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension 23:411, 1994
227. O'Sullivan JB, Harrap SB: Resetting blood pressure in spontaneously hypertensive rats. The role of bradykinin. Hypertension 25:162, 1995
228. Siebeck M, Cheronis JC, Fink E, Kohl J, Spies B, Spannagl M, Jochum M, Fritz H: Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J Appl Physiol 77:2675, 1994
229. Wang J, Xiong W, Yang Z, Davis T, Dewey MJ, Chao J, Chao L: Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23:236, 1994
230. Ma JX, Yang Z, Chao J, Chao L: Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein. J Biol Chem 270:451, 1995
231. Chao J, Tillman DM, Wang MY, Margolius HS, Chao L: Identification of a new tissue-kallikrein-binding protein. Biochem J 239:325, 1986
232. Chao J, Chai KX, Chen LM, Xiong W, Chao S, Woodley-Miller C, Wang LX, Chao L: Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem 265:16394, 1990
233. Zhou GX, Chao L, Chao J: Kallistatin: A novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem 267:25873, 1992
234. Wang C, Chao L, Chao J: Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats [see comments]. J Clin Invest 95:1710, 1995
235. Xiong W, Chao J, Chao L: Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension 25:715, 1995
236. Puri RN, Gustafson EJ, Zhou FX, Bradford H, Colman RF, Colman RW: Inhibition of thrombin-induced platelet aggregation by high molecular weight kininogen. Trans Assoc Am Phys 100:232, 1987
237. Coller BS: Effects of tertiary amine local anesthetics on von Willebrand factor-dependent platelet function: Alteration of membrane reactivity and degradation of GPIb by a calcium-dependent protease(s). Blood 60:731, 1982
238. Puri RN, Matsueda R, Umeyama H, Bradford HN, Colman RW: Modulation of thrombin-induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol-protease inhibitory sequence of kininogens and S-(3-nitro-2-pyridinesulfenyl)-cysteine. Biochem Biophys Res Commun 162:1017, 1989
239. Matsueda R, Umeyama H, Puri RN, Bradford HN, Colman RW: Design and synthesis of a kininogen-based selective inhibitor of thrombin-induced platelet aggregation. Pept Res 7:32, 1994
240. Charo IF, Feinman RD, Detwiler TC: Interrelations of platelet aggregation and secretion. J Clin Invest 60:866, 1977
241. Schmaier AH, Meloni FJ, Nawarawong W, Jiang YP: PPACK-thrombin is a noncompetitive inhibitor of alpha-thrombin binding to human platelets. Thromb Res 67:479, 1992
242. Bradford HN, DeLa Cadena RA, Kunapuli SP, Dong JF, Lopez JA, Colman RW: Human kininogens regulate thrombin binding to platelets through the GPIb-IX complex. Blood 90:1508, 1997
243. Majima M, Sunahara N, Harada Y, Katori M: Detection of the degradation products of bradykinin by enzyme immunoassays as markers for the release of kinin in vivo. Biochem Pharmacol 45:559, 1993
244. Shima C, Majima M, Katori M: A stable metabolite, Arg-Pro-Pro-Gly-Phe, of bradykinin in the degradation pathway in human plasma. Jpn J Pharmacol 60:111, 1992
245. Niewiarowski S, Prou-Wartelle O: Role of the contact factor (Hageman factor) in fibrinolysis. Thromb Diath Haemorrh 3:593, 1959
246. Colman RW: Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 35:273, 1969
247. Mandle RJ Jr, Kaplan AP: Human plasma prekallikrein: Mechanism of activation by Hageman factor and participation in Hageman-factor-dependent fibrinolysis. J Biol Chem 252:6097, 1977
248. Goldsmith G, Saito H, Ratnoff OD: The activation of plasminogen by Hageman FXII (factor XII) and Hageman factor fragments. J Clin Invest 62:54, 1978
249. Mandle RJ Jr, Kaplan AP: Hageman-factor-dependent fibrinolysis: Generation of fibrinolytic activity by the interaction of human activated factor XI and plasminogen. Blood 54:850, 1979
250. Gurewich V, Johnstone M, Loza JP, Pannell R: Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett 318:317, 1993
251. Lin Y, Harris RB, Van W, McCrae KR, Zhang H Colman RW: High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood 90:690, 1997
252. Higazi A, Cohen RL, Henkin J, Kniss D, Schwartz BS, Cines DB: Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor. J Biol Chem 21:17375, 1995
253. Vroman L, Adams A: Possible involvement of fibrinogen and proteolysis in surface activation: A study with the recording ellipsometer. Thromb Diath Haemorrh 18:510, 1967
254. Schmaier AH, Silver L, Adams AL, Fischer GC, Munoz PC, Vroman L, Colman RW: The effect of high molecular weight kininogen on surface-adsorbed fibrinogen. Thromb Res 33:51, 1984
255. Brash JL, Scott CF, ten Hove P, Wojciechowski P, Colman RW: Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces: Role of the contact and fibrinolytic systems. Blood 71:932, 1988
256. Yung LL, Lim F, Khan MMH, Kunapuli SP, Rick L, Colman RW, Cooper SL: Neutrophil adhesion on surfaces preadsorbed with high molecular weight kininogen under well-defined flow conditions. Immunopharmacology 32:9, 1996
257. Donaldson VH, Evans RR: Biochemical abnormality in hereditary angioneurotic edema. Am J Med 35:37, 1963
258. Ratnoff OD, Lepow IH: Some properties of an esterase derived from preparations of the first component of complement. J Exp Med 106:327, 1955
259. Landerman NS Hereditary angioneurotic edema. I. Case reports and review of the literature. J Allergy Clin Immunol 33:316, 1962
260. Schapira M, Sliver LD, Scott CF, Schmaier AH, Prograis L, Curd J, Colman RW: Prekallikrein activation and high molecular weight kininogen consumption in hereditary angioedema. N Engl J Med 308:1050, 1983
261. Cugno M, Hack CE, de Boer JP, Eerenberg AJ, Agostini A, Cicardi M: Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med 121:38, 1993
262. Berrettini M, Lammle B, White T, Heeb MJ, Schwarz HP, Zuraw B, Curd J, Griffin JH: Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunblotting with monoclonal antibodies. Blood 68:455, 1986
263. Fields AP, Ghebrehiwet B, Kaplan AP: Kinin formation in hereditary angioedema plasma: Evidence aginst kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J Allergy Clin Immunol 72:54, 1983
264. Rapaport S, Aas K, Owen PA: Effect of glass upon the activation of various plasma clotting factors. J Clin Invest 34:9, 1955
265. Gjonnaess H: Cold-promoted activation of factor VII. III. Relation to the kallikrein system. Thromb Diath Haemorrh 28:182, 1972
266. Seligsohn U, Osterud B, Brown SF, Griffin JH, Rapaport S: Activation of human factor VII in plasma and in purified systems. J Clin Invest 64:239, 1979
267. Weiss R, Kaplan AP: The effect of C1 inhibitor upon Hageman factor autoactivation. Blood 68:239, 1986
268. Kalter ES, Daha MR, Verhoef J, Bouma BN: Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 151:1019, 1985
269. Colman RW: The role of plasma proteases in septic shock. N Engl J Med 320:1207, 1989
270. Carvalho AC, DeMarinis S, Scott CF, Silver LD, Schmaier AH, Colman RW: Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. J Lab Clin Med 112:270, 1988
271. Mason JW, Colman RW: The role of Hageman factor in disseminated intravascular coagulation induced by septicemia, neoplasia, or liver disease. Thromb Diath Haemorrh 26:325, 1971
272. O'Donnell TF, Clowes GH, Talamo RC, Colman RW: Kinin activation in the blood of patients with sepsis. Surg Gynecol Obstet 143:539, 1976
273. Colman RW, Edelman R, Scott CF, Gilman RH: Plasma kallikrein activation and inhibition during typhoid fever. J Clin Invest 61:287, 1978
274. Schapira M, Gardaz JP, Py P, Lew PD, Perrin LH, Suter PM: Prekallikrein activation in the adult respiratory distress syndrome. Bull Eur Physiopathol Respir 21:237, 1985
275. Rao AK, Schapira M, Clements ML, Niewiarowski S, Budzynski AZ, Schmaier AH, Harpel PC, Blackwelder WC, Scherrer JR, Sobel E: A prospective study of platelets and plasma proteolytic systems during the early stages of Rocky Mountain spotted fever. N Engl J Med 318:1021, 1988
276. Nuijens JH, Huijbregts CC, Eerenberg Belmer AJ, Abbink JJ, Strack van Schijndel RJ, Felt Bersma RJ, Thijs LG, Hack CE: Quantification of plasma factor XIIa-C1(-)-inhibitor and kallikrein-C1(-)-inhibitor complexes in sepsis. Blood 72:1841, 1988
277. Kaufman N, Page JD, Pixley RA, Schein R, Schmaier AH, Colman RW: Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 77:2660, 1991
278. DeLa Cadena RA, Suffredini AF, Page JD, Pixley RA, Kaufman N, Parrillo JE, Colman RW: Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood 81:3313, 1993
279. Pixley RA, DeLa Cadena RA, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor FB Jr, Colman RW: Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol 140:1, 1992
280. Pixley RA, DeLa Cadena RA, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor FB Jr, Colman RW: The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 91:61, 1993
281. Colman RW, Scott CF, Pixley RA, DeLa Cadena RA: Effect of heparin on the inhibition of the contact system enzymes. Ann NY Acad Sci 556:95, 1989
282. Wachtfogel YT, Harpel PC, Edmunds LH Jr, Colman RW: Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasminalpha 2-plasmin-inhibitor complexes during cardiopulmonary by-pass. Blood 73:468, 1989
283. Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds LH Jr: Aprotinin inhibits the contact, neutrophil and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 106:1, 1993
284. Wachtfogel YT, Hack CE, Nuijens JH, Kettner C, Reilly TM, Knabb RM, Bischoff R, Tschesche H, Wenzel H, Kucich U, Edmunds LH Jr, Colman RW: Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am J Physiol 268:H1352, 1995
285. DeLa Cadena RA, Laskin KJ, Pixley RA, Sartor RB, Schwab JH, Back N, Bedi GS, Fisher RS, Colman RW: Role of kallikreinkinin system in pathogenesis of bacterial cell wall-induced inflammation. Am J Physiol 260:G213, 1991
286. DeLa Cadena RA, Stadnicki A, Uknis AB, Sartor RB, Kettner CA, Adam A, Colman RW: Inhibition of plasma kallikrein prevents peptidoglycan-induced arthritis in the Lewis rat. FASEB J 9:446, 1995
287. Sartor RB, DeLa Cadena RA, Green KD, Stadnicki A, Davis SW, Schwab JH, Adam AA, Raymond P, Colman RW: Selective kallikrein-kinin system activation in inbred rats differentially susceptible to granulomatous enterocolitis. Gastroenterology 110:1467, 1996
288. Stadnicki A, DeLa Cadena RA, Sartor RB, Bender D, Kettner CA, Rath HC, Adam A, Colman RW: Selective plasma kallikrein inhibitor attenuates acute intestinal inflammation in Lewis rat. Dig Dis Sci 41:912, 1996
289. Jansen PM, Pixley RA, Brouwer M, DeJong IW, Chang AK, Hack CE, Taylor FB Jr, Colman RW: Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 87:2337, 1996
290. Goodnough LT, Saito H, Ratnoff OD: Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: A report of 21 patients and a review of 50 previously reported cases [Review]. Medicine (Baltimore) 62:248, 1983
291. Mannhalter C, Fisher M, Hopmeier P, Deutch E: Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1:259, 1987
292. Lammle B, Wuillemin WA, Huber I, Krauskopf M, Zurcher C, Pflugshaupt R, Furlan M: Thromboembolism and bleeding tendency in congenital factor XII deficiency: A study on 74 subjects from 14 Swiss families. Thromb Haemost 65:117, 1991
293. Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M: The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 68:285, 1992
294. von Kanel R, Wuillemin WA, Furlan M, Lammle B: Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis 3:555, 1992
295. Jespersen J, Munkvad S, Pedersen OD, Gram J, Kluft C: Evidence for a role of factor XII-dependent fibrinolysis in cardiovascular diseases. Ann NY Acad Sci 667:454, 1992
296. Munkvad S, Jespersen J, Gram J, Kluft C: Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: A randomized placebo-controlled study. J Am Coll Cardiol 17:957, 1991